Biotech

Latest Articles

Basilea scores $268M BARDA backing for antifungals, antibiotics

.Basilea Pharmaceutica's job developing brand new antifungals has obtained a considerable improvemen...

Capricor markets Europe rights to late-stage DMD therapy for $35M

.Having already gathered up the USA civil liberties to Capricor Therapies' late-stage Duchenne muscu...

FDA scraps adcomm for Applied's rare health condition medication

.After pushing the selection date for Applied Rehabs' metabolic ailment medication govorestat, the F...

Novo inks $600M NanoVation bargain to study genetic medicines ex-liver

.Novo Nordisk is continuing its own push right into hereditary medications, consenting to compensate...

Innovent hyperlinks cytokine to colon cancer cells actions

.Innovent Biologics has actually helped make the instance that its own checkpoint inhibitor-cytokine...

Merck, Daiichi ADC reaches target in stage 3 lung cancer cells study

.A stage 3 trial of Daiichi Sankyo as well as Merck &amp Co.'s HER3-directed antibody-drug conjugate...

Rakovina deepens artificial intelligence concentrate along with collab to choose cancer aim ats

.5 months after Rakovina Rehabs rotated toward expert system, the cancer-focused biotech has actuall...

Ascendis' dwarfism medicine smash hits in stage 3, endangers BioMarin

.Ascendis Pharma has emerged as a prospective threat to BioMarin's Voxzogo, stating phase 3 developm...

Despite ph. 3 miss out on, Alkeus views path ahead for eye ailment possession

.Though Alkeus Pharmaceuticals' oral eye illness possession fell short to significantly decrease geo...

Kairos goes social with $6M IPO to cash trials of cancer cells drug

.With a triad of biotechs reaching the Nasdaq on Friday, it was actually effortless to miss out on a...

Vaccine and Keytruda combo reliable in squamous cell cancer

.Immune system checkpoint preventions are actually the superheroes of cancer therapy. Medications li...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of considerable management hirings, firings ...

Regeneron's Opdualag opponent presents 57% response rate

.Regeneron is actually back with long-lasting follow-up for its LAG-3 inhibitor and also PD-1 preven...

AstraZeneca posts information on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early examine the efficiency of its in-house antibody-drug co...

iTeos- GSK's TIGIT star reveals purposeful renovation

.After declaring a period 3 launch based upon favorable midstage end results, iTeos and GSK are even...

More collaborative FDA may increase rare condition R&ampD: record

.The FDA should be even more available and also collaborative to let loose a surge in commendations ...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It's an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bica...

Atea's COVID antiviral neglects to halt hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has actually neglected an additional COVID-19 trial, but the biotec...

Neurocrine's bid to save mental illness possibility fails

.Neurocrine Biosciences' mental illness program pivot has actually failed. The biotech was actually ...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually created a late entry to the radioligand gathering, paying out one hundred milli...